The Arkansas approach to therapy of patients with multiple myeloma

McElwain, 1983, High-dose intravenous melphalan for plasma-cell leukaemia and myeloma, Lancet, 2, 822, 10.1016/S0140-6736(83)90739-0 Barlogie, 1986, High-dose melphalan with autologous bone marrow transplantation for multiple myeloma, Blood, 67, 1298, 10.1182/blood.V67.5.1298.bloodjournal6751298 Barlogie, 1987, High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma, Blood, 70, 869, 10.1182/blood.V70.3.869.869 Ventura, 1990, High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma, Bone Marrow Transplantation, 5, 265 Jagannath, 1992, Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support, Blood, 80, 1666, 10.1182/blood.V80.7.1666.1666 Vesole, 1994, High dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants, Blood, 84, 950, 10.1182/blood.V84.3.950.950 Barlogie, 1997, Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma, Blood, 89, 789, 10.1182/blood.V89.3.789 Barlogie, 2006, Long-term outcome results of the first tandem autotransplant trial for multiple myeloma, British Journal of Haematology, 135, 1365, 10.1111/j.1365-2141.2006.06271.x Pui, 2006, Drug therapy: treatment of acute lymphoblastic leukemia, The New England Journal of Medicine, 354, 166, 10.1056/NEJMra052603 Harousseau, 1992, Double-intensive therapy in high-risk multiple myeloma, Blood, 79, 2827, 10.1182/blood.V79.11.2827.bloodjournal79112827 Fermand, 1989, Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft, Blood, 73, 20, 10.1182/blood.V73.1.20.20 Cunningham, 1998, A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results, British Journal of Haematology, 102, 495, 10.1046/j.1365-2141.1998.00795.x Ellison, 1968, Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults, Blood, 32, 507, 10.1182/blood.V32.4.507.507 Alexanian, 1969, Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens, The Journal of the American Medical Association, 208, 1680, 10.1001/jama.208.9.1680 Barlogie, 2006, Effect of adding thalidomide to the treatment of multiple myeloma with tandem autotransplants, The New England Journal of Medicine, 10, 1021, 10.1056/NEJMoa053583 Barlogie, 2007, Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3, British Journal of Haematology, 138, 176, 10.1111/j.1365-2141.2007.06639.x Powles, 1995, Maintenance therapy for remission in myeloma with Intron A following high dose melphalan and either an autologous bone marrow transplantation or pheripheral stem cell rescue, Stem Cells, 13, 114 Singhal, 1999, Antitumor activity of thalidomide in refractory multiple myeloma, The New England Journal of Medicine, 341, 1565, 10.1056/NEJM199911183412102 Barlogie, 2001, Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients, Blood, 98, 492, 10.1182/blood.V98.2.492 Richardson, 2003, A phase 2 study of bortezomib in relapsed, refractory myeloma, The New England Journal of Medicine, 348, 2609, 10.1056/NEJMoa030288 Zangari, 2003, VTD regimen comprising Velcade + thalidomide and added DEX for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma relapsing after autologous transplant, Blood, 102, 236a Barlogie, 2004, Treatment of multiple myeloma, Blood, 103, 20, 10.1182/blood-2003-04-1045 Lee, 2003, DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma, Journal of Clinical Oncology, 21, 2732, 10.1200/JCO.2003.01.055 Hideshima, 2005, Identification and validation of novel therapeutic targets for multiple myeloma, Journal of Clinical Oncology, 23, 6345, 10.1200/JCO.2005.05.024 Tricot, 1995, Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities, Blood, 86, 4250, 10.1182/blood.V86.11.4250.bloodjournal86114250 Zhan, 2006, The molecular classification of multiple myeloma, Blood, 108, 2020, 10.1182/blood-2005-11-013458 Zhan, 2007, Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis, Blood, 109, 1692, 10.1182/blood-2006-07-037077 Shaughnessy, 2007, A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, 109, 2276, 10.1182/blood-2006-07-038430 Zhan, 2005, The Gene Expression Signatures (GEP) of Whole Bone Marrow Biopsies (Bx) from Patients with Multiple Myeloma (MM) in Remission Reflect Disease Risk and Therapy, Blood, 106, 1547, 10.1182/blood.V106.11.1547.1547 Shaughnessy, 2007, Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics, British Journal of Haematology, 137, 530, 10.1111/j.1365-2141.2007.06586.x Walker, 2007, Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications, Journal of Clinical Oncology, 25, 1121, 10.1200/JCO.2006.08.5803 Tian, 2003, The role of Wnt/beta-catenin signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma, The New England Journal of Medicine, 349, 2483, 10.1056/NEJMoa030847 Haessler J, Shaughnessy JD, Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clinical Cancer Research, in press. Pineda-Roman, 2007, Complete Resonse in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smoldering disease, British Journal of Haematology, 136, 393, 10.1111/j.1365-2141.2006.06441.x van Rhee, 2007, High serum free-light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis, Blood, 110, 827, 10.1182/blood-2007-01-067728 Attal, 1996, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma, The New England Journal of Medicine, 335, 91, 10.1056/NEJM199607113350204 Child, 2003, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma, The New England Journal of Medicine, 348, 1875, 10.1056/NEJMoa022340 Attal, 2003, Single versus double autologous stem cell transplantation for multiple myeloma, The New England Journal of Medicine, 349, 2495, 10.1056/NEJMoa032290 Barlogie, 2006, Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies, Blood, 107, 2633, 10.1182/blood-2005-10-4084 Richardson, 2007, New drugs for myeloma, The Oncologist, 12, 663, 10.1634/theoncologist.12-6-664 Arzoumanian, 2006, Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM), Blood, 108, 3561, 10.1182/blood.V108.11.3561.3561 Pineda-Roman, 2006, Retrospective analysis of fractionated high-dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM), Blood, 108, 3102, 10.1182/blood.V108.11.3102.3102 Mitsiades, 2003, The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications, Blood, 101, 2377, 10.1182/blood-2002-06-1768 Pineda-Roman, 2007, High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in more than 3000 patients, Journal of Clinical Oncology, 25, 8043, 10.1200/jco.2007.25.18_suppl.8043 Badros, 2001, Results of autologous stem cell transplant in multiple myeloma patients with renal failure, British Journal of Haematology, 114, 822, 10.1046/j.1365-2141.2001.03033.x Siegel, 1999, Age is not a prognostic variable with autotransplants for multiple myeloma, Blood, 93, 51, 10.1182/blood.V93.1.51 Fassas, 2005, Metronomic chemoimmunotherapy in a patient with refractory Waldenström's macroglobulinemia, Leukemia & Lymphoma, 46, 1675, 10.1080/10428190500217825 Finger, 2004, Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinatory of cell groth and cell cycle progression, Oncogene, 23, 3151, 10.1038/sj.onc.1207542 Govindarajan, 1995, Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma, British Journal of Haematology, 95, 349, 10.1046/j.1365-2141.1996.d01-1891.x Shaughnessy, 2006, In vivo changes in gene expression profiles (GEP) after bortezomib (V) for multiple myeloma (MM): differential effects on plasma cells (PC) and microenvironment (ME), ASCO Meeting Abstracts, 24, 7603 Barlogie, 2007, Cytogenetically defined myelodysplasia after melphalan-based autotranplants for multiple myeloma linked to poor hematopoietic stem cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989, Blood